for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Luminex Corporation

LMNX.OQ

Latest Trade

22.49USD

Change

0.31(+1.40%)

Volume

240,352

Today's Range

22.03

 - 

22.61

52 Week Range

19.41

 - 

30.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
22.18
Open
22.16
Volume
240,352
3M AVG Volume
4.54
Today's High
22.61
Today's Low
22.03
52 Week High
30.72
52 Week Low
19.41
Shares Out (MIL)
45.05
Market Cap (MIL)
999.14
Forward P/E
-123.22
Dividend (Yield %)
1.62

Next Event

Dividend For LMNX.OQ - 0.0900 USD

Latest Developments

More

Luminex Submits Aries Mrsa Assay For FDA Clearance

Luminex Corp Q1 GAAP Earnings Per Share $0.07

Luminex Q4 GAAP Loss Per Share $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Luminex Corporation

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry

Software & Programming

Contact Info

12212 Technology Blvd, 512-219-8020

+1.512.2494741

http://www.luminexcorp.com/

Executive Leadership

George Walter Loewenbaum

Independent Chairman of the Board

Nachum Shamir

President, Chief Executive Officer, Director

Harriss T. Currie

Chief Financial Officer, Senior Vice President - Finance, Treasurer

Richard W. Rew

Senior Vice President, General Counsel and Corporate Secretary

Todd C. Bennett

Senior Vice President - Global Sales and Customer Operations

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.3K

2018

0.3K

2019(E)

0.3K
EPS (USD)

2016

0.320

2017

0.920

2018

0.410

2019(E)

-0.180
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.13
Price To Book (MRQ)
2.10
Price To Cash Flow (TTM)
51.86
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-1.32
Return on Equity (TTM)
-1.21

Latest News

BRIEF-Luminex Corp Reports Q1 GAAP Earnings Per Share $0.30

* Q1 EARNINGS PER SHARE VIEW $0.20 -- THOMSON REUTERS I/B/E/S

BRIEF-Luminex Corp Reports Q4 GAAP Loss Per Share $0.07

* ORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Luminex Corporation receives FDA clearance for Aries Group A Strep Assay

* Luminex Corporation receives FDA clearance for Aries Group A Strep Assay Source text for Eikon: Further company coverage:

BRIEF-Luminex Corp reports Q3 earnings per share $0.40

* Luminex Corporation reports third quarter 2017 financial results

BRIEF-Zicom Group says settlement agreement has been reached​ on ‍lawsuit filed by Luminex Corporation against Curiox Biosystems

* Refers to lawsuit filed by luminex corporation against curiox biosystems; advises settlement agreement has been reached Source text for Eikon: Further company coverage:

BRIEF-Zicom Group updates on litigation against Curiox Biosystems Inc​

* Luminex Corporation has filed an original complaint against Curiox Biosystems Inc

BRIEF-Luminex Corporation Q2 earnings per share $0.13

* Luminex Corporation reports second quarter 2017 financial results

BRIEF-Luminex Corporation receives FDA clearance for ARIES C. difficile assay

* Luminex Corporation receives FDA clearance for ARIES C. difficile assay

BRIEF-Luminex Verigene gram-positive and gram-negative blood culture panels get reimbursement approval in Japan

* Luminex Corporation's verigene gram-positive and gram-negative blood culture panels receive reimbursement approval in Japan

BRIEF-Luminex Corp Q1 gaap earnings per share $0.21

* Luminex Corp says Q1 total Verigene related revenue of $10.5 million; growth of 59% over its Q1 2016

BRIEF-Luminex Corp announces cash dividend of $0.06

* Luminex corp - board of directors intends for company to pay a regular quarterly cash dividend of $0.06 to holders of its common stock, Source text for Eikon: Further company coverage:

BRIEF-Luminex Corporation posts Q3 adj. earnings per share $0.21

* Luminex Corp- revised full-year revenue guidance factors in a contribution from Nanosphere of between $7.5 million and $8.5 million in Q4 of 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up